Belite Bio Inc ADR reports a Return on Equity (ROE) of -11.34%.

What is BLTE's dividend yield?

Belite Bio Inc ADR offers a dividend yield of 0.00%.

What is BLTE's Quality Score?

Our AI rates BLTE's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy BLTE?

Our AI Timing Score for BLTE is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does BLTE belong to?

Belite Bio Inc ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Belite Bio Inc ADR (BLTE) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

BLTE AI Analysis Summary

Our AI summary for BLTE: Belite Bio Inc ADR (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -11.34%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

BLTE

Belite Bio Inc ADR

US:NASDAQ STOCK Healthcare >> Biotechnology News 91

USD 154.79

-3.82 (-2.41%) Day Change

Watchlist Portfolio Compare Chart

0.02

D/E

-11.3%

ROE

-11.1%

ROA

0.00%

Div Yield

BELITE BIO INC ADR
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 154.79 Price -3.82 (-2.41%) Day Change	NEWS SCORE: 91

BLTE, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	91
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	154.79
PBV / Sector	7.99 / 44,219.29
Earning Per Share	-2.20

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	26.15 M GREAT
Average 1W Daily Value	29.54 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.22
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-11.13 / 185,260.96
ROA Average (%) / Sector	-21.36 / 36,684.70
ROA Change Average (%) / Sector	-14.54 / 422,221.66
ROE (%) / Sector	-11.34 / 243,762.23
ROE Average (%) / Sector	-22.33 / 48,758.47
ROE Change Average (%) / Sector	-15.28 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:14
Symbol	BLTE
Name	BELITE BIO INC ADR
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	40.09 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	6,357.90 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 12750 High Bluff Drive, San Diego, CA, United States, 92130

Phone: 858 246 6240

Website: https://www.belitebio.com

Sector: Healthcare >> Biotechnology

Description: Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.